FULC
NASDAQ HealthcareFulcrum Therapeutics, Inc. - Common Stock
Biotechnology
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
�� 市场数据
| 价格 | $8.29 |
|---|---|
| 成交量 | 1,028,761 |
| 市值 | 552.12M |
| 贝塔系数 | 3.270 |
| RSI（14日） | 70.0 超买 |
| 200日均线 | $8.84 |
| 50日均线 | $8.41 |
| 52周最高 | $15.74 |
| 52周最低 | $3.17 |
| Forward P/E | -5.17 |
| Price / Book | 1.58 |
🎯 投资策略评分
FULC 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (98/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 💰 Dividend Daddy (1/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 FULC in your text
粘贴任何文章、记录或帖子 — 工具将提取 FULC 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.